+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Middle East & Africa Human Insulin Market - Growth, Trends and Forecast (2019 - 2024)

  • ID: 4763978
  • Report
  • Region: Africa, East Africa, Middle East
  • 100 pages
  • Mordor Intelligence
UP TO OFF
until Jul 01st 2019
1 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Eli Lilly
  • Exir
  • Julphar
  • Novo Nordisk
  • Sanofi
  • MORE
Market Overview
  • The Middle East & Africa human insulin market has potential to grow, and it is expected to grow at approximately 4% CAGR during the forecast period (2019-2024).
  • Nearly 100 million people around the world need insulin, including all the people living with Type 1 Diabetes, and between 10-25% of people with Type 2 Diabetes.
  • Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford it and cannot access it.
  • People with Type 1 Diabetes need Insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle habits to prevent complications.
Scope of the Report

The Middle East & Africa human insulin market is segmented by Product Type (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), and by Region, which covers Saudi Arabia, Iran, Egypt, South Africa, Oman & the Rest of Middle East & Africa.

Key Market Trends

Increasing Diabetes Prevalence is Expected to Boost the Market in the Forecast Period
  • The prevalence of Type 2 Diabetes mellitus (T2DM) has increased dramatically during the last two decades - a fact driven by the increased prevalence of obesity, the primary risk factor for T2DM. Many reports and surveys documented a drastic increase in the diabetic population based on lifestyle habits. High growth in urbanization has worsened physical inactivity, and in turn, making diabetes is a major health concern.
  • The R&D in the insulin segments are growing year-on-year, where scientists are trying to bring out the best molecule for patients use by curbing the maximum extent of side effects, and by increasing their efficiency.
Biosimilar Insulins hold a Significant Market Share
  • Biosimilar insulin is highly popular in the Middle East & Africa region because of its low cost as compared to branded insulins.
  • The Middle Eastern & African countries have substantial economic diversity. The per-capita expenditure on diabetes in the region is low, although some countries in the region have managed to modify their healthcare expenditure to include biologic and biosimilar therapies.
  • Biosimilars have grown with a high CAGR of 13% in the historical period because of consistent efforts by local manufacturers to capture the highly consolidated market.
Competitive Landscape
  • The Middle East & Africa insulin market is dominated by Novo Nordisk, Sanofi and Eli Lilly. However, there are many local players like Julphar, Sedico, and Exir, who hold a significant market share.
  • Julphar is developing Insulin Glargine Biosimilar, which is expected to launch in 2020.


As part of this package, any purchases made up to 30th June will receive the following:

1) Free update of the report in 6 months on request 

2) Free Market Estimate sheet excel data sheet
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Eli Lilly
  • Exir
  • Julphar
  • Novo Nordisk
  • Sanofi
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Insulin (Value and Volume, 2012-2024)
5.1.1.1 Basal or Long-acting Insulins
5.1.1.1.1 Lantus (Insulin Glargine)
5.1.1.1.2 Levemir (Insulin Detemir)
5.1.1.1.3 Toujeo (Insulin Glargine)
5.1.1.1.4 Tresiba (Insulin Degludec)
5.1.1.1.5 Basaglar (Insulin Glargine)
5.1.1.2 Bolus or Fast-acting Insulins
5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.1.2.2 Humalog (Insulin Lispro)
5.1.1.2.3 Apidra (Insulin Glulisine)
5.1.1.3 Traditional Human Insulins
5.1.1.3.1 Novolin/Actrapid/Insulatard
5.1.1.3.2 Humilin
5.1.1.3.3 Insuman
5.1.1.4 Biosimilar Insulins
5.1.1.4.1 Insulin Glargine Biosimilars
5.1.1.4.2 Human Insulin Biosimilars
5.1.1.5 Insulin Combinations
5.1.1.5.1 NovoMix (Biphasic Insulin Aspart)
5.1.1.5.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.1.5.3 Xultophy (Insulin Degludec and Liraglutide)
5.2 Geography
5.2.1 Middle East & Africa (Value and Volume, 2012-2024)
5.2.1.1 Saudi Arabia
5.2.1.1.1 Basal or Long-acting Insulins
5.2.1.1.2 Bolus or Fast-acting Insulins
5.2.1.1.3 Traditional Human Insulins
5.2.1.1.4 Biosimilar Insulins
5.2.1.1.5 Insulin Combinations
5.2.1.2 Iran
5.2.1.2.1 Basal or Long-acting Insulins
5.2.1.2.2 Bolus or Fast-acting Insulins
5.2.1.2.3 Traditional Human Insulins
5.2.1.2.4 Biosimilar Insulins
5.2.1.2.5 Insulin Combinations
5.2.1.3 Egypt
5.2.1.3.1 Basal or Long-acting Insulins
5.2.1.3.2 Bolus or Fast-acting Insulins
5.2.1.3.3 Traditional Human Insulins
5.2.1.3.4 Biosimilar Insulins
5.2.1.3.5 Insulin Combinations
5.2.1.4 Oman
5.2.1.4.1 Basal or Long-acting Insulins
5.2.1.4.2 Bolus or Fast-acting Insulins
5.2.1.4.3 Traditional Human Insulins
5.2.1.4.4 Biosimilar Insulins
5.2.1.4.5 Insulin Combinations
5.2.1.5 South Africa
5.2.1.5.1 Basal or Long-acting Insulins
5.2.1.5.2 Bolus or Fast-acting Insulins
5.2.1.5.3 Traditional Human Insulins
5.2.1.5.4 Biosimilar Insulins
5.2.1.5.5 Insulin Combinations
5.2.1.6 Rest of Middle and Africa
5.2.1.6.1 Basal or Long-acting Insulins
5.2.1.6.2 Bolus or Fast-acting Insulins
5.2.1.6.3 Traditional Human Insulins
5.2.1.6.4 Biosimilar Insulins
5.2.1.6.5 Insulin Combinations

6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.2 Eli Lilly
7.1.3 Sanofi
7.1.4 Boehringer Ingelheim
7.1.5 Julphar
7.1.6 Exir
7.1.7 Sedico

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • Boehringer Ingelheim
  • Julphar
  • Exir
  • Sedico
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4763978
Adroll
adroll